Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.67 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.67 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22158729 | 0.92 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| SCHEMBL4317842 | 0.89 | TLR7 (0.53) | TLR7TLR8NUDT1 | |
| SCHEMBL5451703 | 0.89 | TLR7 (0.56) | TLR7TLR8NUDT1 | |
| SCHEMBL4130348 | 0.89 | TLR7 (0.57) | TLR7TLR8NUDT1 | |
| SCHEMBL1890829 | 0.88 | TLR7 (0.52) | TLR7TLR8NUDT1 | |
| SCHEMBL5617120 | 0.87 | TLR7 (0.54) | TLR7TLR8NUDT1 | |
| SCHEMBL22158693 | 0.87 | TLR7 (0.52) | TLR7TLR8NUDT1 | |
| SCHEMBL1895853 | 0.87 | TLR7 (0.53) | TLR7TLR8NUDT1 | |
| SCHEMBL4313723 | 0.87 | TLR7 (0.55) | TLR7TLR8NUDT1 | |
| SCHEMBL4245396 | 0.87 | TLR7 (0.55) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210330664-A1 | PHARMACEUTICAL COMPOSITIONS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-10-28 | — | — | US | claimed |
| US-20210163476-A1 | IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2021-06-03 | — | — | US | claimed |
| CN-110769827-A | Pharmaceutical composition | 博笛生物科技有限公司 | 2020-02-07 | — | — | CN | claimed |
| US-20150361077-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2015-12-17 | — | — | US | claimed |
| EP-2950649-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | Wellstat Therapeutics Corporation (US) | 2015-12-09 | — | — | EP | claimed |
| WO-2014120995-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-08-07 | — | — | WO | claimed |
| WO-2008052126-A2 | OINTMENT COMPRISING PHOSPHATIDYLSERINE AS ACTIVE AGENT FOR CANCER TREATMENT | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-05-02 | — | — | WO | claimed |
| WO-2025103490-A1 | N-OXIDE IMMUNE AGONISTS ACTIVATION BY RADIOTHERAPY | Beijing Changping Laboratory (CN) | 2025-05-22 | — | — | WO | disclosed |
| US-12295970-B2 | Imidazoquinoline compounds and prodrugs thereof | UNIVERSITY OF KANSAS (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250034139-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2025-01-30 | — | — | US | disclosed |
| US-12139483-B2 | Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | PHARMA CINQ, LLC (US) | 2024-11-12 | — | — | US | disclosed |
| US-12030940-B2 | Immunotherapeutic tumor treatment method | NEKTAR THERAPEUTICS (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | disclosed |
| US-5977366-A | 1-substituted, 2-substituted 1H-imidazo[4,5-c] quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0582581-B1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING & MFG (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0872478-A2 | Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5741909-A | PHARMACEUTICAL COMPOSITIONS WHICH ACT AS ANTIVIRAL AGENTS, INDUCE BIOSYNTHESIS OF INTERFERON AND INHIBIT TUMOR FORMATION IN ANIMALS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| US-5605899-A | VIRICIDES, BIOSYNTHESIS OF INTERFERONS, ANTITUMOR AGENTS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5389640-A | Viricides, antitumor agents | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| WO-1992015582-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163476-A1 | IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | NOD1, NLRP3, AADAC | TLR7 456/4885TLR8 63/4885NUDT1 713/4885 |
| US-20250034139-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AADAC, CASP1, AAAS | TLR7 380/4885TLR8 87/4885NUDT1 428/4885 |
| US-20150361077-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AADAC, CASP1, AAAS | TLR7 380/4885TLR8 87/4885NUDT1 428/4885 |
| US-12295970-B2 | Imidazoquinoline compounds and prodrugs thereof | TLR7, TLR8, TLR1 | TLR7 1/4885TLR8 2/4885NUDT1 592/4885 |
| US-12139483-B2 | Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | NOD1, NLRP3, AADAC | TLR7 456/4885TLR8 63/4885NUDT1 713/4885 |
| US-12030940-B2 | Immunotherapeutic tumor treatment method | CD274, TLR7, PDCD1LG2 | TLR7 2/4885TLR8 5/4885NUDT1 2779/4885 |
| US-20210330664-A1 | PHARMACEUTICAL COMPOSITIONS | PLA2G2C, SFPQ, PRNP | TLR7 4767/4885TLR8 4832/4885NUDT1 346/4885 |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885NUDT1 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.